Weekly Research Analysts’ Ratings Changes for Novavax (NVAX)

Several brokerages have updated their recommendations and price targets on shares of Novavax (NASDAQ: NVAX) in the last few weeks:

• 11/7/2026 – Novavax was upgraded by Wall Street Zen from “hold” to “buy”.
• 11/6/2026 – Novavax had its “buy” rating reaffirmed by B. Riley Financial. They now have a $16.00 price target on the stock, down from $18.00.
• 11/2/2026 – Novavax had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 10/27/2026 – Novavax had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 10/15/2026 – Novavax had its “sell” rating reaffirmed by Citigroup. They now have a $8.00 price target on the stock, up from $7.00.
• 9/12/2026 – Novavax was upgraded by Wall Street Zen from “sell” to “hold”.

Novavax Stock Down 6.3%

NVAX stock opened at $10.20 on Wednesday. Novavax, Inc. has a 52-week low of $6.20 and a 52-week high of $13.39. The firm has a market cap of $1.68 billion, a P/E ratio of -22.17 and a beta of 2.65. The company’s 50-day simple moving average is $10.61 and its 200-day simple moving average is $9.35.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.16. The company had revenue of $68.30 million during the quarter, compared to analysts’ expectations of $50.42 million. Novavax had a negative return on equity of 14.82% and a negative net margin of 18.64%. Novavax’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.25) EPS. On average, analysts anticipate that Novavax, Inc. will post -0.02 earnings per share for the current fiscal year.

Novavax, Inc. is a biotechnology company focused on developing vaccines for infectious diseases. Its technology combines recombinant protein-based vaccine antigens with Matrix-M, a saponin-based adjuvant designed to strengthen the immune response. The company’s best-known product is Nuvaxovid, a protein-based COVID-19 vaccine authorized in the United States and other markets. Novavax also develops additional vaccine candidates, including a combination COVID-19 and influenza vaccine. Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax serves international markets through regulatory approvals and commercial partnerships.